Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 4, keine Gesamtzahl für „Approximately“
Suchtreffer
Begriffe & Kennungen
Enzalutamide Viatris · 4.5 · The full induction potential of enzalutamide may not occur until approximately 1 month after the start of trea
Eintrag öffnenEporatio · 4.8 · Summary of the safety profile Approximately 9% of patients can be expected to experience an adverse reaction.
Eintrag öffnenEsbriet · 4.5 · Approximately 70–80% of pirfenidone is metabolised via CYP1A2 with minor contributions from other CYP isoenzym
Eintrag öffnenEtcamah · 4.8 · 10 nadir at approximately 14 days and generally recovered following treatment cessation in a similar time cour
Eintrag öffnenEvista · 4.8 · In the RUTH study, venous thromboembolic events occurred at a frequency of approximately 2.0 % or 3.88 cases p
Eintrag öffnenFarydak · 4.5 · Farydak metabolism is through both non-CYP and CYP mediated routes. Approximately 40% of panobinostat is metab
Eintrag öffnenFarydak · 4.5 · The panobinostat fraction metabolised through CYP3A4 is approximately 40%. In clinical studies in multiple mye
Eintrag öffnenGalafold · 4.8 · The most common adverse reaction was headache, which was experienced by approximately 10% of patients who rece
Eintrag öffnenGardasil 9 · 4.8 · In 7 clinical studies, individuals were administered Gardasil 9 on the day of enrolment and approximately 2 an
Eintrag öffnenGazyvaro · 4.8 · The study MO40597 was designed to characterize the safety profile of short duration infusions (approximately 9
Eintrag öffnenGobivaz · 4.8 · 101 varies (approximately 2 years for 50 mg dose, approximately 3 years for 100 mg dose) as patients may have
Eintrag öffnenGobivaz · 4.8 · 44 In the controlled periods of pivotal trials and through approximately 4 years of follow-up, the incidence o
Eintrag öffnenGobivaz · 4.8 · Malignancies other than lymphoma In the controlled periods of pivotal trials and through approximately 4 years
Eintrag öffnenGobivaz · 4.8 · Malignancies other than lymphoma In the controlled periods of pivotal trials and through approximately 4 years
Eintrag öffnenGobivaz · 4.8 · Malignancies other than lymphoma In the controlled periods of pivotal trials and through approximately 4 years
Eintrag öffnenGobivaz · 4.8 · Throughout this section, median duration of follow-up (approximately 4 years) is generally presented for all g
Eintrag öffnenGobivaz · 4.8 · Throughout this section, median duration of follow-up (approximately 4 years) is generally presented for all g
Eintrag öffnenGobivaz · 4.8 · Throughout this section, median duration of follow-up (approximately 4 years) is generally presented for all g
Eintrag öffnenGobivaz · 4.8 · Throughout this section, median duration of follow-up (approximately 4 years) is generally presented for all g
Eintrag öffnenGotenfia · 4.8 · 13 varies (approximately 2 years for 50 mg dose, approximately 3 years for 100 mg dose) as patients may have s
Eintrag öffnen